Un­der-the-radar NiKang Ther­a­peu­tics bursts on­to the scene with $200M Se­ries C from in­vestors that screams IPO

A se­cre­tive biotech out of Wilm­ing­ton, DE, closed a mas­sive, nine-fig­ure Se­ries C on Wednes­day, and it comes from an in­vestor syn­di­cate that is high­ly in­dica­tive of IPO prepa­ra­tions.

NiKang Ther­a­peu­tics se­cured $200 mil­lion in its lat­est fund­ing round, the com­pa­ny an­nounced, bring­ing blue-chip in­vestors such as RA Cap­i­tal Man­age­ment, Per­cep­tive, Cor­morant As­set Man­age­ment and Ecor1 in­to the fold. The round comes about a month and a half af­ter NiKang ap­point­ed a new chief fi­nan­cial of­fi­cer in Kelsey Chen, for­mer­ly a man­ag­ing di­rec­tor at Cor­morant.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER